

04/14/2008 11:57 FAX 6123051228

MUETING RAASCH GEBHARDT

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.00100101	Serial No.: 10/780,797
	Applicant(s): MUNN et al.	Confirmation No.: 1508
	Application Filing Date: 02/17/04	Group: 1614
	Information Disclosure Statement mailed:	April <u>14</u> , 2008

U.S. PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
		NONE					

FOREIGN PATENT DOCUMENTS

Examiner Initial	Copy Enclosed	Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
		NONE						

OTHER DOCUMENTS (Including Authors, Title, Date, Pertinent Papers, etc.)

Examiner Initial	Copy Enclosed	Document Description
	X	“Chemotherapy Before Breast Surgery is Valuable.” CANCERWISE, The University of Texas MD Anderson Cancer Center, Featured Article. Retrieved from the Internet on February 25, 2008. Retrieved from http://www.cancerwise.org/july_2005/display.cfm?id=8FD089A2-41F1-4B7C-844D5550459E1368&method=displayFull&color=green . 4 pages.
	X	“New Treatments” Seattle Cancer Care Alliance, Breast Cancer Program. Retrieved from the Internet on February 25, 2008. Retrieved from http://www.seattleccca.org/patientsandfamilies/adultCare/clinicalProgs/breastCancer/newTreatments/NeoadjuvantChemotherapy.htm . 1 page.
	X	Chemotherapy Information/Chemotherapy Terms. Retrieved from the Internet on February 25, 2008. Retrieved from http://www.chemocare.com/whatis/important_chemotherapy_terms.asp . 2 pages.
	X	Hou et al., “The immunosuppressive effects of 10 mg/kg cyclophosphamide in Wistar rats,” 2007. <i>Environ. Toxicology and Pharmacology</i> , 24:30-36.

EXAMINER	Date Considered
-----------------	------------------------

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

APR 14 2008

OMB No. 0651-0011

Page 2 of 2

INFORMATION DISCLOSURE STATEMENT	Atty. Docket No.: 275.00100101	Serial No.: 10/780,797
	Applicant(s): MUNN et al.	Confirmation No.: 1508
	Application Filing Date: 02/17/04	Group: 1614
	Information Disclosure Statement mailed:	April <u>14</u> , 2008

Examiner Initial	Copy Enclosed	Document Description
	X	On-Line Article. 2008. MedicineNet.com. Information on Generic Name: Cyclophosphamide, Brand Name: Cytoxan. Retrieved from the Internet on April 9, 2008. Retrieved from http://www.medicinenet.com/script/main/art.asp?articlekey=12343&pf=3&page=1 . 2 pages.
	X	Moyo et al., "High-dose cyclophosphamide for refractory autoimmune hemolytic anemia," 2002, <i>Blood</i> , 100(2):704-706.
	X	Nygaard et al., "Blood and spleen lymphocytes as targets for immunotoxic effects in the rat - a comparison," 2002. <i>Toxicology</i> , 174:153-161.
	X	Ochalek, "Divergence between delayed-type hypersensitivity (DTH) to polyoma tumor-associated antigen and antitumor efficacy in polyoma-bearing recipients of therapeutic non-cytolytic, DTH-mediating lymphocytes," 1993. <i>Immunol. Lett.</i> 38(2):97-102.
	X	On-Line Article. "Taxotere®/Cytoxan® Superior to Standard Adriamycin®/Cytoxan as Adjuvant Therapy in Breast," <i>CancerConsultants.com</i> . Retrieved from the internet on February 29, 2008. Retrieved from http://professional.cancerconsultants.com/print.aspx?id=35701 2 pages.
	X	Reiner et al., "Pulse Cyclophosphamide Therapy for Refractory Autoimmune Thrombocytopenic Purpura," 1995. <i>Blood</i> , 85(2):351-358.

EXAMINER	Date Considered

*Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.